Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NINDS NS072030, NINDS R01NS103226, NINDS R01NS103226, NINDS R01NS103226)
Simons Foundation
Article History
Received: 29 January 2020
Accepted: 21 August 2020
First Online: 28 September 2020
Competing interests
: B.L.S. is a founder of and holds private equity in Optogenix. Tapered fibers commercially available from Optogenix were used as tools in the research.